karppaus.info

Abstract
The purpose of this study is to assess the effects of an alternative approach to type 2 diabetes prevention. Ninety-six patients with prediabetes (age 52 (10) years; 80% female; BMI 39.2 (7.1) kg/m2) received a continuous remote care intervention focused on reducing hyperglycemia through carbohydrate restricted nutrition therapy for two years in a single arm, prospective, longitudinal pilot study. Two-year retention was 75% (72 of 96 participants). Fifty-one percent of participants (49 of 96) met carbohydrate restriction goals as assessed by blood beta-hydroxybutyrate concentrations for more than one-third of reported measurements. Estimated cumulative incidence of normoglycemia (HbA1c <5.7% without medication) and type 2 diabetes (HbA1c ≥6.5% or <6.5% with medication other than metformin) at two years were 52.3% and 3%, respectively. Prevalence of metabolic syndrome, class II or greater obesity, and suspected hepatic steatosis significantly decreased at two years. These results demonstrate the potential utility of an alternate approach to type 2 diabetes prevention, carbohydrate restricted nutrition therapy delivered through a continuous remote care model, for normalization of glycemia and improvement in related comorbidities.

Two-year results further illustrate the effectiveness and sustainability of Virta’s intervention in reversing a variety of metabolic conditions

SAN FRANCISCO, CA (March 2, 2021)—Today Virta Health, the type 2 diabetes reversal leader, announced the publication of new peer-reviewed research in Nutrients. In this publication, Virta reports best-in-class outcomes in diabetes prevention, with only 3% of trial participants progressing to type 2 diabetes (T2D) and over half achieving prediabetes reversal during the first two years. Further, the trial saw strong retention, with 75% of patients retained at the two-year mark.

Notably, these figures far exceed outcomes reported for the National Institutes of Health Diabetes Prevention Program (NIH DPP) and its real-world translation, the National Diabetes Prevention Program (NDPP)—considered the gold standard in prediabetes treatment.

According to the CDC, an estimated 88 million Americans, or about one-third of the population, have prediabetes. Of those patients, as many as 30% will progress to T2D within five years. Today’s publication shows that this high progression rate is not inevitable.

Key outcomes demonstrating the success of Virta’s approach include:

Progression to type 2 diabetes: Over two years, just 3% of Virta’s patients progressed to type 2 diabetes. In the NIH DPP trial, approximately 8% in the lifestyle intervention, 15% in those treated with metformin, and 22% in the control group progressed to T2D.
Prediabetes reversal: During the two-year period, 52% of Virta patients achieved prediabetes reversal, by reducing HbA1c below the diagnostic threshold for prediabetes without medication. Reaching this result, even temporarily, is associated with significantly lower risk of T2D progression, cardiovascular disease, myocardial infarction, stroke, and death.
Weight loss: Virta patients experienced an average weight loss of 11.3% at two years, more than doubling the NDPP’s 5% goal for prediabetes.‍
Retention: One and two-year trial retention was 80% and 75%, respectively. For context, NDPP one-year retention was 13.2%.
“The overwhelming number of patients who either achieve normal blood sugar or avoid progression to type 2 diabetes further demonstrates the effectiveness of Virta’s reversal treatment on a variety of metabolic conditions,” said Dr. Robert Ratner, Chief Medical Officer at Virta Health. “Nutrition modifications can be hard to sustain, but the remarkable adherence and retention demonstrate both the acceptability and durability of the Virta approach in both prevention and treatment of diabetes."

Today’s news supports Virta’s recent expansion of clinical offerings. Virta now offers T2D reversal, prediabetes reversal, and obesity treatment to members of its enterprise, health plan, and government customers. The company also offers diabetes management, with personalized guidance and an option for a seamless transition to Virta’s T2D reversal treatment when patients are ready.

“Before joining Virta five years ago, I’d tried everything to get my prediabetes under control, but my numbers kept creeping up,” said Cathy McKinnis, a clinical trial participant. “Thanks to Virta, I’ve reversed my prediabetes and lost 50 pounds. This treatment really works, and Virta provides the support to make it last.”

For more information on Virta’s research and treatment to reverse type 2 diabetes and prediabetes, please visit www.virtahealth.com.

Giving people at risk of T2D choice is A GREAT THING.

Over 2 years, 97% of Virta prediabetes patients avoided progression to type 2 diabetes. Using the National Institutes of Health Diabetes Prevention Program (NIH DPP) trial as context¹, one way to frame this is that nearly 3x more people progress to T2D in the NIH DPP lifestyle intervention (approximately 5x more in the Metformin intervention), compared to Virta patients.

Because their main advertising $ are from processed food and drug companies, while Virta reduces their profits.